Peptide Comparison
EnalaprilvsBPC-157
The blood pressure champion that helped millions breathe easier and live longer
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Enalapril
2.5 mg–40 mg mg
BPC-157
250–500 mcg
Frequency
Enalapril
Once daily
BPC-157
Once daily
Administration
Enalapril
Oral tablet
BPC-157
Subcutaneous injection
Cycle Length
Enalapril
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
Enalapril
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Enalapril
Strong human trials (Phase 3 or FDA approved)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Cardiovascular Health
Long-term Protection
Quality of Life
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Enalapril
Molecular Formula
C20H28N2O5
Molecular Weight
376.4 g/mol
Half-Life
Enalapril: 1 hour; Enalaprilat (active form): 11 hours effective half-life
Bioavailability
Approximately 60% oral bioavailability when taken by mouth
CAS Number
75847-73-3
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Enalapril
BPC-157
Applications
Best
suited for
Enalapril
Managing hypertension to prevent serious complications
Enalapril is particularly well-suited for individuals focused on managing hypertension to prevent serious complications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating heart failure and improving survival rates
Enalapril is particularly well-suited for individuals focused on treating heart failure and improving survival rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Protecting organs from damage caused by high blood pressure
Enalapril is particularly well-suited for individuals focused on protecting organs from damage caused by high blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Enalapril
Common
- Dry cough
- Dizziness
- Fatigue
- Hyperkalemia
- Angioedema
Serious
- Severe allergic reaction
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Enalapril
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Enalapril is an FDA-approved ACE inhibitor with safety data spanning over 40 years of clinical use and post-market surveillance in millions of hypertensive patients. Persistent dry cough occurs in 10-20% of patients, caused by kinase II inhibition and bradykinin accumulation. Hyperkalemia is a serious risk, particularly in renal impairment, diabetes, or concurrent NSAID/potassium-sparing diuretic use—potassium monitoring is essential. Angioedema (0.1-0.2%) is a rare but life-threatening emergency, absolute contraindication for future ACE inhibitor use. Hypotension can occur in volume-depleted patients or those on concurrent vasodilators. Acute kidney injury risk exists in patients with bilateral renal artery stenosis or single kidney. Fetal teratogenicity is well-documented in pregnancy.
Contraindications
- xPregnancy (causes serious fetal harm)
- xHistory of angioedema with ACE inhibitors
- xSevere renal dysfunction
- xConcurrent use with certain other blood pressure medications
- xPotassium supplementation without medical supervision
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Enalapril if...
- Managing hypertension to prevent serious complications
- Treating heart failure and improving survival rates
- Protecting organs from damage caused by high blood pressure
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health